RE:RE:RE:RE:CAR-T updateStuff is happening in bringing pelareorep into a Phase 3 PanCan supported clinical trial in metastatic pancreatic cancer in combination with paclitaxel and the CPI Tecentriq. With earlier Phase 2 GOBLET-1 results reporting that pelareorep demonstrated a 69% ORR over paclitaxel alone, ESMO will further report on these findings and set the stage for the filing for an Accelerated Approval as the ONCY/PanCan Phase 3 mPC begins enrollment into what will turn into a confirmatory trial.
An earlier Phase 2 trial involving pelareorep + paclitaxel + Keytruda demonstrated that G12D Kras proteins in pancreatic cancer and G12V Kras proteins in colorectal cancers were biomarkers that specifically responded to pelareorep treatment.
Today it has been rumored the Big Pharma company Sanofi was looking into acquiring Mirati Therapeutics- a Kras focused company. Should this happen in the near future, ONCY and its PanCan Phase 3 mPC should garner significantly more attention, since Kras has always been considered an undruggable target. Mirati and ONCY are now changing that perception.